This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.
In this video, Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations of the different toxicity profiles.
Agarwal spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Adjuvant Nivolumab Misses DFS End Point in Locally Advanced High-Risk RCC
January 27th 2024Treatment with nivolumab did not reach the primary endpoint of disease-free survival when compared with placebo in patients with localized renal cell carcinoma at high risk of relapse after nephrectomy in the phase 3 CheckMate 914 trial.